Sareum Holdings plc share price (AIM: SAR) was down after the clinical-stage biotechnology company specializing in kinase inhibitors for autoimmune diseases and cancer, provided an operational update at its AGM held on 19 December 2024. The company highlighted significant advancements in its lead programmes, SDC-1801 and SDC-1802, alongside progress with its licensed asset, SRA737.
SDC-1801: TYK2/JAK1 Inhibitor for Autoimmune Diseases
- The Phase 1 clinical trial of SDC-1801 successfully concluded in 2024, demonstrating strong safety and pharmacokinetic data. The drug achieved therapeutic blood plasma levels with no serious adverse events reported, supporting potential once-daily dosing.
- With additional funding of £3.4 million and a £1 million Australian tax credit, Sareum will prepare for Phase 2 trials. This includes drug product synthesis and toxicology studies, set for completion by mid-2025.
- Intellectual property milestones include U.S. and China patents, enhancing protection of the drug’s chemical structure and crystalline forms.
SDC-1802: Cancer Immunotherapy
- SDC-1802, targeting cancer and immunotherapy applications, is progressing through translational and preclinical studies funded by the October 2024 equity raise. Sareum anticipates further updates during this period.
SRA737: Licensed Selective Chk1 Inhibitor
- Sareum’s co-development partner, CRT Pioneer Fund, licensed SRA737 to a U.S.-based biopharma company in January 2024. Sareum received an upfront fee of $137,500 and is eligible for a 27.5% share of additional payments, totaling up to $1 million in cash and 500,000 shares upon milestones.
Outlook
Sareum says it is well-positioned to advance its strong pipeline, bolstered by recent funding and strategic intellectual property gains. The company is optimistic about the therapeutic potential of its kinase inhibitors to address unmet needs in autoimmune diseases and cancer.
AGM Webcast
A live webcast for investors is available on the Investor Meet Company platform, with a Q&A session to follow.
This update reflects Sareum’s momentum toward delivering innovative therapies and driving shareholder value.
Richard is the founder of the Good Money Guide (formerly Good Broker Guide), one of the original investment comparison sites established in 2015. With a career spanning two decades as a broker, he brings extensive expertise and knowledge to the financial landscape.
Having worked as a broker at Investors Intelligence and a multi-asset derivatives broker at MF Global (Man Financial), Richard has acquired substantial experience in the industry. His career began as a private client stockbroker at Walker Crips and Phillip Securities (now King and Shaxson), following internships on the NYMEX oil trading floor in New York and London IPE in 2001 and 2000.
Richard’s contributions and expertise have been recognized by respected publications such as The Sunday Times, BusinessInsider, Yahoo Finance, BusinessNews.org.uk, Master Investor, Wealth Briefing, iNews, and The FT, among many others.
Under Richard’s leadership, the Good Money Guide has evolved into a valuable destination for comprehensive information and expert guidance, specialising in trading, investment, and currency exchange. His commitment to delivering high-quality insights has solidified the Good Money Guide’s standing as a well-respected resource for both customers and industry colleagues.
You can contact Richard at richard@goodmoneyguide.com
